While NewAmsterdam Pharma Company NV has overperformed by 0.08%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, NAMS rose by 141.07%, with highs and lows ranging from $27.29 to $9.72, whereas the simple moving average jumped by 26.90% in the last 200 days.
On May 15, 2024, TD Cowen started tracking NewAmsterdam Pharma Company NV (NASDAQ: NAMS) recommending Buy. A report published by Scotiabank on March 14, 2024, Initiated its previous ‘Sector Outperform’ rating for NAMS. Guggenheim also rated NAMS shares as ‘Buy’, setting a target price of $30 on the company’s shares in an initiating report dated January 18, 2024. Piper Sandler Initiated an Overweight rating on January 16, 2024, and assigned a price target of $37. RBC Capital Mkts initiated its ‘Outperform’ rating for NAMS, as published in its report on October 30, 2023.
Analysis of NewAmsterdam Pharma Company NV (NAMS)
There are several well-rounded types of analysis and research techniques that can be used to gain a clear view of NewAmsterdam Pharma Company NV’s future performance, with equity being one of the most critical indicators. Taking into account the quick ratio of the company, currently set at 10.61, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
As an indicator of volatility for any stock, average volume can also be very valuable, and NAMS is recording an average volume of 666.41K. On a monthly basis, the volatility of the stock is set at 7.00%, whereas on a weekly basis, it is put at 8.88%, with a gain of 33.42% over the past seven days. Furthermore, long-term investors anticipate a median target price of $42.88, showing growth from the present price of $24.71, which can serve as yet another indication of whether NAMS is worth investing in or should be passed over.
How Do You Analyze NewAmsterdam Pharma Company NV Shares?
Apart from looking at the fundamentals, you should also pay attention to the number of company employees who own shares. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 52.17%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 41.33% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
NAMS shares are owned by institutional investors to the tune of 41.33% at present.
